OR WAIT null SECS
July 22, 2024
Article
In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.
Podcast
Bludorn joins Lungcast to review the increasing effects and signs of heat-related illness amid record-high temperatures.
July 07, 2024
After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.
July 05, 2024
Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, review a recent trial comparing upadacitinib to dupilumab for patients with atopic dermatitis.